Enlaza Therapeutics
<p>The War-Lock platform works by incorporating proprietary unnatural amino acids into therapeutic proteins. These unnatural amino acids act as tethering points that enable the biologic to covalently bind to its target. The amino acids are engineered to have low intrinsic reactivity so they will not indiscriminately bind off-target proteins. However, when the biologic engages its specific target, the unnatural amino acid is brought into close proximity and can react to form a permanent, covalent bond. This results in the biologic being “locked” onto its target.</p>
<p>Enlaza believes this covalent binding approach offers significant advantages over traditional biologics. Because they remain continuously bound to their targets, covalent biologics can exhibit sustained target occupancy and prolonged pharmacological effect. This opens the possibility for less frequent dosing and improved patient convenience. Additionally, because any unbound drug is rapidly cleared from systemic circulation, covalent biologics may avoid some of the on-target/off-tissue effects that limit standard biologics. Enlaza is using these advantages to develop safer and more effective treatments across a range of disease indications.</p>
<p><a href="https://medium.com/@axialxyz/enlaza-therapeutics-322521386ac8"><strong>Read More</strong></a></p>